Lung cancer

Lung cancer originates from the uncontrolled proliferation of cells within the lung tissue. These cells typically arise from the epithelial cells lining the bronchi, bronchioles, or alveoli. The transformation into cancerous cells involves a series of genetic mutations that disrupt normal cell cycle regulation, leading to loss of differentiation and uncontrolled growth.

These mutations can be caused by various carcinogens, which damage the DNA, or they can occur spontaneously during cell division. The two main categories are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being more common and further divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each with distinct cellular characteristics and behaviors.

While lung tumors have likely existed for centuries, lung cancer as a recognized disease gained prominence in the early 20th century, coinciding with the rise of widespread cigarette smoking. Early physicians like Dr. Fritz Lickint and Dr.

Alton Ochsner began to document the strong association between smoking and lung cancer in the 1930s and 1940s. However, it wasn't until the landmark 1964 report by the U.S. Surgeon General that the causal link between smoking and lung cancer was definitively established for the public.

This marked a turning point, leading to public health campaigns and regulations aimed at reducing smoking rates, though the disease remains a significant challenge due to its latency period and the addictive nature of nicotine.

Lung cancer is a leading cause of cancer-related death worldwide, posing a massive burden on global health systems. Its high mortality rate is often attributed to late diagnosis, as early-stage symptoms can be subtle or mimic other respiratory conditions. The economic impact is also substantial, encompassing healthcare costs for treatment, lost productivity due to illness and premature death, and the societal costs associated with supporting affected individuals and families.

Furthermore, the disproportionate impact on certain populations, often linked to socioeconomic factors and historical patterns of smoking, highlights ongoing health disparities that require targeted interventions and policy changes.

Once established, lung cancer cells can invade surrounding lung tissue, leading to local symptoms like cough, hemoptysis (coughing up blood), and chest pain. The disease progresses through stages based on tumor size, lymph node involvement, and the presence of distant metastases. Cancer cells can metastasize via two primary routes: the lymphatic system, where they travel to nearby lymph nodes, and the bloodstream, allowing them to reach distant organs.

Common sites for lung cancer metastasis include the brain, bones, liver, and adrenal glands, significantly complicating treatment and worsening prognosis. Understanding these pathways is crucial for effective staging and treatment planning.

Modern management of lung cancer involves a multidisciplinary approach. Diagnosis typically begins with imaging studies like chest X-rays and CT scans, followed by tissue confirmation through biopsy, often guided by bronchoscopy or needle aspiration. Molecular testing of tumor tissue is now standard, identifying specific genetic mutations (e.g., EGFR, ALK, KRAS) that can be targeted by precision therapies.

Treatment modalities include surgery (for early-stage disease), radiation therapy, chemotherapy, targeted drug therapy, and immunotherapy. Immunotherapy, which harnesses the patient's immune system to fight cancer, has revolutionized treatment for many patients, particularly those with advanced NSCLC, offering improved survival rates and quality of life.